Seed and Early-Stage Biotech Investment
Experienced | Efficient | Focused
Great Track Record: 25+ biotech start-ups in the portfolio
Genesis @ 4242 Campus Point, San Diego, Nov. 14, 2018
To successfully launch a biotech company, in addition to a brilliant idea and a great team, getting access to seed funding and drug R&D technology platforms are two important milestones. Whether you are an entrepreneur seeking early stage investment or you just have a project idea and would like to know how to take it to the next level, you are cordially invited to the Viva Biotech Partnering Reception. Click here
for your complementary registration.
o Experienced – Biotech executives and scientific leaders-turned-investors
o Efficient – Streamlined due diligence and team decision-making process
o Focused – Invest only in biotech startups seeking early stage funding
How Viva can help you succeed
o Systematic and scientific incubation mechanism
o Easy access to talents and technology platforms
5:00-5:50 pm: Pre-event Reception (drinks and Hors D’oeuvres will be served)
5:50-6:00 pm: Welcome Remarks
Mrs. Yinghong Gao, Executive Director, Business Development of Viva Biotech
6:00-6:30 pm: Viva Biotech Early Stage Investment and Incubation Mechanism
Dr. Cheney Mao, CEO and founder of Viva Biotech
6:30-6:45 pm: How Does the Process Work – From a Founder’s Perspective
Dr. Yimin Zou, CEO and founder of VersaPeutics
6:45-7:30 pm: Q&A and Panel Discussion on San Diego Biotech Startup Ecosystem
- Dr. Cheney Mao, Founder, Chairman, chief executive officer and Executive Director
- Dr. Yimin Zou, Neurobiology Professor UCSD; CEO and founder of VersaPeutics
- Dr. Rubén Flores, Director of Commercialization of the Office of Innovation and Commercialization (OIC) at UCSD
7:30-8:00 pm: Networking Reception
To submit your investor deck, please contact Yinghong Gao
. One-on-one meeting may be arranged if there is a match
About Viva Biotech: Established in 2008, Viva Biotech is an innovation-driven technology platform companydedicated to support early stage drug discovery serving clients around the globe. Viva adopts an innovative business model combining fee-for-service (FFS) and equity-for-service (EFS) risk-sharing and direct investment approaches. Viva is headquartered in Shanghai, China with another lab in Jiaxing and an office in Cambridge, USA
Dr. Cheney Mao
Dr. Yimin Zou
Dr. Rubén Flores
Cheney Mao, Ph.D. Founder, Chairman, chief executive officer and Executive Director
Dr. MAO Chen Cheney, the Chairman, chief executive officer and an executive Director of our Company, is mainly responsible for the overall strategic planning and business development of the Group. Dr. Mao has over 20 years experiences in CRO industry.
Dr. Mao obtained his bachelor’s degree and master’s degree from Fudan University in the PRC, and obtained his Ph.D. degree in biochemistry from Cornell University in the U.S.. After graduation, he served as a director of the Department of Structural Biology of Parker Hughes Institute. He also served as a reviewer on the U.S. National Institutes of Health Review Panel ZRG1 AARR-1(50) in relation to AIDS-related structural biology projects grants.
Dr. Yimin Zou, Neurobiology Professor UCSD; CEO and founder of VersaPeutics
Dr. Yimin Zou graduated from Shanghai Fudan University and was a CUSBEA (China and United States Biochemistry Examination and Application Program) student and received his Ph. D. from University of California, Davis and San Diego, in 1995. He did his postdoctoral fellowship at University of California, San Francisco from 1996 to 2000 and was an Assistant and Associate Professor at the University of Chicago from 2000 to 2006. He joined the faculty of UCSD in July, 2006. He is currently a neurobiology professor of UCSD and the CEO and founder of VersaPeutics.
Dr. Rubén Flores, Director of Commercialization of the Office of Innovation and Commercialization (OIC) at UCSD
Dr. Flores earned his doctorate in chemistry and biochemistry at UCLA, and began his career in the San Diego biotechnology industry at BD Biosciences Pharmigen. He has held a variety of positions with increasing responsibility in R&D, marketing, business development and technology commercialization. His professional career also includes Biosite (now Inverness), where he helped design, initiate, negotiate and monitor clinical trials; and later joined Chemicon (now Millipore-Sigma), where he managed R&D, worldwide clinical-trial operations, and marketing activities for diagnostic products. While at Millipore-Sigma, Dr. Flores also created the world-wide Scientific Collaborations and Business Development group, tasked with working with academic partners across the globe for the development of early-stage academic research.
Most recently, Dr. Flores served as Vice President of Business Development and Technology Transfer for the Los Angeles BioMedical Research Institute at Harbor UCLA Medical Center, where he focused on fostering the entrepreneurial ecosystem for startups in Los Angeles. He was named the Director of Commercialization of the Office of Innovation and Commercialization (OIC) at UC San Diego.